Physiomics Share Discussion Threads

[bri15] 07/8/2024 14:00

Thanks Laura on LSE,and a few others,pump was good.

[bri15] 07/8/2024 13:45

In essence I had £4K in here bought at 0.65 and sold £3K earlier, leaving the £1K just in case it does keep rising,as for Apta,well i about £50 down on that which is nothing compared to the gains to be had with that one.

[sharewatching] 07/8/2024 12:53

So. In essence what you mean is ‘I don’t own any PYC but I’m heavily underwater in APTA so please buy some there’.

[bri15] 07/8/2024 12:22

Pump over, profit into Apta 😁

[gkace] 07/8/2024 12:05

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec.https://x.com/mylesmcnulty/status/1821133127579820448?s=46

[le mass du pap] 06/8/2024 13:31

Just tried to get some of these but can't get a quote. Anyone else the same? Looks to have consolidated long enough around the placing price and ridiculously cheap. Guess it's fill or kill.

[pugugly] 03/7/2024 08:24

T101 - I was negative back in 2020 - Time has proved me right - Yet another squashed bio-tech minnow.

[eezymunny] 03/7/2024 08:20

Nice shafting for the idiotic nasty little rampers on here. Decades of losses and still they try to pump it....

[terminator101] 03/7/2024 07:37

50% discounted placing huh gerbils.

If only there had been warnings about this lifestyle pish.

Nearly 3 decades and not a single penny of profit eh. That takes some doing.

[davevt] 07/6/2024 17:07

'The project is valued at £161,580 and is anticipated to be completed over the next five months. The project, and associated contract award, is one of the two referred to in the Company's trading update on 3 May 2024'

So, already priced in to the share price.

[thiopia] 07/6/2024 10:02

7 June 2024

Physiomics plc

Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has been awarded a significant contract by a new UK-based biotech client. This client sits at the forefront of AI-driven design and development of novel therapies across various therapeutic areas. The project involves the use of our proprietary Virtual Tumour technology to help guide the Phase 1b/2 dosing regimens for one of their oncology assets and benchmark it against the competition. The project is valued at £161,580 and is anticipated to be completed over the next five months. The project, and associated contract award, is one of the two referred to in the Company's trading update on 3 May 2024.

Dr Peter Sargent, CEO, commented: "We at Physiomics are very excited about starting our first project with this exciting new client and we look forward to working with their team over the coming months and hopefully on further programmes in the future".

[thiopia] 30/5/2024 00:31

Previously:-

Congratulations to our client Numab Therapeutics AG on this fantastic achievement! Great to have worked with Numab on the NM26 programme

“We have worked with Physiomics on a PK/PD modelling project for our molecule NM26-2198, intended for use in patients with inflammatory disease. The work has been highly productive, valuable and enjoyable. The Physiomics team are knowledgeable, helpful and dedicated to provide the expertise required to bring the project to fruition. Based on this excellent collaboration we will certainly be working with Physiomics again.”

Daniel Snell, VP Translational Science

Now:-

Numab is thrilled to announce that Johnson & Johnson has entered into a definitive agreement to acquire Yellow Jersey Therapeutics, a wholly-owned subsidiary of Numab that holds the rights to NM26. NM26 is an investigational first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis, discovered and engineered through Numab’s proprietary MATCH™ technology platform.

Johnson & Johnson will pay a purchase price of $1.25 billion and will gain the full rights to develop, manufacture and commercialize NM26 globally for atopic dermatitis and follow-on indications. This acquisition further validates our discovery and engineering platform and its potential to bring novel multi-specific antibodies to underserved patient populations.

[criticalthinker1] 25/5/2024 20:00

It just takes time. The Bletchley Declaration will be most apparent re Physiomics future. Wheels within wheels but I have a good holding here and content to see the longer game play out.

[davevt] 25/4/2024 00:33

Critical, the last time you posted, the price was higher than this, so what do you mean nice and steady?

[ant15] 23/4/2024 10:34

Spot on CT1

[criticalthinker1] 23/4/2024 10:02

Nice and steady 👌

[davevt] 19/3/2024 20:06

Just because people may get excited and buy shares and The price goes up doesn't mean revenues are linked to mcap, because this share is currently sitting lower, with a lower mcap than previously, AFTER releasing news of new contracts and revenues.

So that just blew your theory didn't it..

[le mass du pap] 19/3/2024 13:15

It's not just good news, it's great news. Existing big pharma client putting more business the company's way. More of that please! Market makers persisting with the daft spread, buys actually above 1.3p.

[simonsmithiv] 19/3/2024 12:54

It's new business, new money, new income and a significant proportion of the company's entire market capitalisation, so of course it's significant. No doubt if they'd lost the client you'd be saying it's significant.

A quick look at your posts shows you've been negative on everything PYC related for some time, and only PYC. So you've clearly got something against this company in particular and therefore your comments cannot be taken seriously.

There's one on every board.